# AstraZeneca Calquence Phase III ELEVATE-TN trial meets primary endpoint

- Link: https://www.directorstalkinterviews.com/astrazeneca-calquence-phase-iii-elevate-tn-trial-meets-primary-endpoint/412784254
- Published: 2019-06-06T07:27:47+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
today announced positive results from the Phase III ELEVATE-TN trial of _Calquence_(
acalabrutinib) in patients with previously-untreated chronic lymphocytic leukaemia(
CLL), the most common type of leukaemia in adults.^(1) This is the second _Calquence_
pivotal trial in CLL to meet its primary endpoint early, following the positive 
results of the ASCEND trial, announced in May.

The trial met its primary endpoint; _Calquence_ in combination with obinutuzumab
demonstrated astatistically-significant and clinically-meaningful improvement in
progression-free survival (PFS) when compared with the chemotherapy-based combination
of chlorambucil and obinutuzumab.

The trial also met a key secondary endpoint showing _Calquence_ monotherapy achieved
a statistically-significant and clinically-meaningful improvement in PFS compared
to the chemotherapy and obinutuzumab regimen.

The safety and tolerability of _Calquence_ was consistent with its established profile.

José Baselga, Executive Vice President, Oncology R&D said: “These findings confirm
the superiority of _Calquence_ as a monotherapy and also in combination over standard-
of-care treatments for chronic lymphocytic leukaemia. The positive results from 
both the ELEVATE-TN and ASCEND trials will serve as the foundation for regulatory
submissions later this year.”

AstraZeneca plans to present detailed results from ELEVATE-TN at a forthcoming medical
meeting. Additionally, AstraZeneca will present full results from the Phase III 
ASCEND clinical trial in relapsed or refractory CLL as a late-breaking abstract 
at the upcoming European Hematology Association (EHA) Annual Congress on 16 June
2019 (Abstract #LB2606).

_Calquence_ is currently approved for the treatment of adults with relapsed or refractory
mantle cell lymphoma (MCL) in the US, Brazil, the UAE, and Qatar and is being developed
for the treatment of CLL and other blood cancers.

**About ELEVATE-TN**

ELEVATE-TN (ACE-CL-007) is a randomised, multicentre, open-label Phase III trial
evaluating the safety and efficacy of _Calquence_ alone or in combination with obinutuzumab
vs. chlorambucil in combination with obinutuzumab in previously-untreated patients
with CLL. In the trial, 535 patients were randomised (1:1:1) into three arms. Patients
in the first arm received chlorambucil in combination with obinutuzumab. Patients
in the second arm received _Calquence_ (100mg twice daily until disease progression)
in combination with obinutuzumab. Patients in the third arm received _Calquence_monotherapy(
100mg twice daily until disease progression).^(2)

The primary endpoint is PFS in the _Calquence_ and obinutuzumab arm compared to 
the chlorambucil and obinutuzumab arm, assessed by an independent review committee(
IRC), and a key secondary endpoint is IRC-assessed PFS in the _Calquence_ monotherapy
arm compared to the chlorambucil and obinutuzumab arm. Other secondary endpoints
include objective response rate, time to next treatment and overall survival.^(2)

**About **_**Calquence**_

_Calquence_ (acalabrutinib) was granted accelerated approval by the US Food and 
Drug Administration (FDA) in October 2017 for the treatment of adult patients with
MCL who have received at least one prior therapy. Continued approval for this indication
may be contingent upon verification and description of clinical benefit in confirmatory
trials.

_Calquence_ is an inhibitor of Bruton tyrosine kinase (BTK). _Calquence_ binds covalently
to BTK, thereby inhibiting its activity.^(3) In B-cells, BTK signalling results 
in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis,
and adhesion.

As part of an extensive clinical development programme, AstraZeneca and Acerta Pharma
are currently evaluating _Calquence_ in 26 company-sponsored clinical trials. _Calquence_
is being developed for the treatment of multiple B-cell blood cancers including 
CLL, MCL, diffuse large B-cell lymphoma, Waldenstrom macroglobulinaemia, follicular
lymphoma, and multiple myeloma and other haematologic malignancies. Several Phase
III clinical trials in CLL are ongoing, including ASCEND, ELEVATE-TN, ELEVATE-RR(
ACE-CL-006) evaluating acalabrutinib vs. ibrutinib in patients with previously-treated
high-risk CLL, and ACE-CL-311 evaluating acalabrutinib in combination with venetoclax
and with/without obinutuzumab in patients with previously-untreated CLL without 
17p deletion or TP53 mutation.

**About chronic lymphocytic leukaemia**

Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia in adults,
with an estimated 191,000 new cases globally and 20,720 new cases in the US annually,
and prevalence that is expected to grow with improved treatment.^(1,4,5,6) In CLL,
too many blood stem cells in the bone marrow become abnormal lymphocytes and these
abnormal cells have difficulty fighting infections.^(1) As the number of abnormal
cells grows there is less room for healthy white blood cells, red blood cells and
platelets.^(1) This could result in anaemia, infection and bleeding.^(1) B-cell 
receptor signalling through BTK is one of the essential growth pathways for CLL.

**About AstraZeneca in haematology**

Leveraging its strength in oncology, AstraZeneca has established haematology as 
one of four key oncology disease areas of focus. The Company’s haematology franchise
includes two US FDA-approved medicines and a robust global development programme
for a broad portfolio of potential blood cancer treatments. Acerta Pharma serves
as AstraZeneca’s haematology research and development arm. AstraZeneca partners 
with like-minded science-led companies to advance the discovery and development 
of therapies to address unmet need.

In October 2018, AstraZeneca and Innate Pharma announced a global strategic collaboration
that included Innate Pharma licensing the US commercial rights of _Lumoxiti_ (moxetumomab
pasudotox-tdfk), and with support from AstraZeneca, will continue EU development
and commercialisation, pending regulatory submission and approval.

**About AstraZeneca in oncology**

AstraZeneca has a deep-rooted heritage in oncology and offers a quickly-growing 
portfolio of new medicines that has the potential to transform patients’ lives and
the Company’s future. With at least six new medicines to be launched between 2014
and 2020, and a broad pipeline of small molecules and biologics in development, 
we are committed to advance oncology as a key growth driver for AstraZeneca focused
on lung, ovarian, breast and blood cancers. In addition to our core capabilities,
we actively pursue innovative partnerships and investments that accelerate the delivery
of our strategy as illustrated by our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers
and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing
the development of personalised combinations, AstraZeneca has the vision to redefine
cancer treatment and one day eliminate cancer as a cause of death.

Share on:
